

| | | | | | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|
| | | | | | | | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|--|

School of Medical and Allied Sciences

Bachelor of Pharmacy

Mid Term Examination - Mar 2024

Duration : 90 Minutes

Max Marks : 30

Sem VIII - BPET8004 - Pharmaceutical Regulatory ScienceGeneral Instructions*Answer to the specific question asked**Draw neat, labelled diagrams wherever necessary**Approved data hand books are allowed subject to verification by the Invigilator*

- 1) Define generic drug. K1 (2)
 - 2) Demonstrate drug discovery process. K2 (2)
 - 3) Infer bioavailability. K2 (2)
 - 4) What is lead optimization? K1 (2)
 - 5) Infer toxicological study. K2 (2)
 - 6) Identify various aspects of innovator drugs. K3 (5)

 - 7) Compare US FDA with CDSCO K4 (5)
- OR**
- Compare ACTD with ICH-CTD. K4 (5)
 - 8) Interpret the clinical phases of drug development. K5 (10)
- OR**
- Access various phases of clinical trials. K5 (10)